APIXABAN
Information current as at: 1 July 2026
PBAC meeting date: November 2026
Submission Details
- Brand name:
-
- Axoran®
- Form and strength:
-
- Oral suspension 1.25 mg per mL, 150 mL
- Submission sponsor:
- ACTOR PHARMACEUTICALS PTY LTD
- Condition/indication:
(therapeutic use) -
- Prevention of stroke or systemic embolism Prevention of recurrent venous thromboembolism Deep vein thrombosis Pulmonary embolism Prevention of venous thromboembolism
- Listing requested:
- To request a new oral liquid suspension form of apixaban for the same indications as the tablet form of apixaban. To request that apixaban oral liquid suspension be considered as an exempt item under section 84AH of the National Health Act 1953. Where a pharmaceutical item is determined to be an exempt item, that pharmaceutical item is excluded from fifteen year Anniversary Price, first new brand and price disclosure reductions. Exempt items are not exempt from five and ten year Anniversary Price reductions.
- Funding program:
- PBS General Schedule
- Request authority level:
- Authority Required (STREAMLINED)
- PBAC Submission type:
- New PBS listing (–)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - November 2026 PBAC meeting
-
2Opportunity for consumer comment:
- Open 22/07/2026 and close 16/09/2026 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Pending PBAC outcome (see PBAC Outcomes)
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID
a1263
Page last updated
23 July 2026
v.9.19